Immunomodulator composition having lupus-pathogenic B cell and antibody modulating effect through combination with immunosuppressant
A pharmaceutical composition using SD217 and FK506 inhibits lupus-associated B cells and autoantibodies, addressing the limitations of current immunosuppressants by improving lupus-related nephritis and thrombosis.
Patent Information
- Application Number
- KR1020220006614
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2022-01-17
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2042-01-17
AI Technical Summary
Current immunosuppressants for autoimmune diseases like lupus are costly, have complex chemical structures, and cause harmful side effects, while new drug development is hindered by the need to suppress specific immune responses without affecting responses to external antigens, and there is no definitive cure for lupus-related nephritis or thrombosis.
A pharmaceutical composition comprising a compound represented by Chemical Formula 1 or its pharmaceutically acceptable salt, which inhibits Germinal Center B cells and Plasma B cells, and reduces the expression of lupus autoantibodies IgG1, IgG2a, and IgG3, using SD217 and FK506 in combination.
The combined treatment effectively inhibits the activity of lupus-associated B cells and reduces autoantibodies, providing a potential therapeutic benefit for lupus-related nephritis and thrombosis.
Smart Images

Figure 112022005835155-PAT00014_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to an immunomodulatory substance composition having the effect of regulating lupus pathogenic B cells and antibodies through combination with an immunosuppressant. Background Technology
[0002] Immunological diseases are conditions in which components of the mammalian immune system cause, mediate, or otherwise contribute to pathological conditions in mammals; in particular, inflammatory disorders are one of the most important health issues worldwide. Inflammation is generally a localized protective response of body tissues against host invasion by external substances or harmful stimuli. Causes of inflammation can be infectious agents such as bacteria, viruses, and parasites; physical causes such as burns or radiation exposure; chemicals such as toxins, drugs, or industrial agents; immunological responses such as allergies and autoimmune reactions; or conditions associated with oxidative stress.
[0003] Inflammation is characterized by pain, reddening, swelling, fever, and the ultimate loss of function in the infected area. These symptoms are the result of a series of complex interactions occurring among the cells of the immune system. Cellular responses consequently generate an interaction network of various groups of inflammatory mediators: proteins (e.g., cytokines), enzymes (e.g., proteases, peroxidases), major basic proteins, adhesion molecules (ICAM, VCAM), lipid mediators (e.g., eicosanoids, prostaglandins, leukotrienes, platelet-activating factor (PAF)), and reactive oxygen species (e.g., hydroperoxide, superoxide anion O2-, nitric oxide (NO), etc.). However, most of these inflammatory mediators are also regulators of normal cellular activity. Therefore, a deficiency in the inflammatory response leads to uncontrolled damage (i.e., infection) to the host, and thus chronic inflammation causes inflammatory diseases mediated partly by the overproduction of several of the aforementioned mediators. Furthermore, autoimmune diseases, a type of immune disorder, are characterized by the immune system attacking its own organs to trigger a spontaneous response. These responses are attributed to the recognition of autoantigens by T lymphocytes, thereby Fluid-phase (autoantigen generation) and cellular-phase (increased cytotoxic activity of lymphocytes and macrophages) immune responses are triggered.
[0004] In cases of autoimmune diseases caused by the destruction of self cells and tissues due to an abnormal immune response to one's own antigens, and organ transplant rejection resulting from an immune response to the transplanted organ, immunosuppressants that inhibit the activation and function of immune cells must be used. Based on fundamental molecular and cellular research on immune responses, three to four immunosuppressants were developed quite some time ago and currently occupy an annual market worth 30 trillion won. Although many multinational pharmaceutical companies are still making significant efforts to develop new immunosuppressants, they have not achieved major success in new drug development, with the exception of a few mAbs currently in the clinical stage. Unlike the development of new drugs for other diseases, which considers efficacy, safety, and disease specificity, the development of immunosuppressants requires considering the additional challenge of suppressing specific immune responses while maintaining the immune response to external antigens, which makes the emergence of new drugs difficult.
[0005] Furthermore, while immunosuppressants such as cyclosporine A are currently in use, they are natural compounds with complex chemical structures that are uneconomical due to high raw material procurement costs and carry the risk of various side effects resulting from long-term administration. Therefore, there is an urgent need for the development of new immunosuppressants that can achieve low toxicity and induce immune tolerance, while also enabling economical production.
[0006] Meanwhile, lupus is an autoimmune disease associated with antibodies that attack connective tissue, linked to the production of antinuclear antibodies (a circulating immune complex) and the activation of the complement system. This disease is systemic and can affect all organ systems, potentially causing severe tissue damage. Patients with lupus may produce autoantibodies with anti-DNA, anti-Ro, and anti-platelet specificity, which can lead to the development of conditions such as glomerulonephritis, arthritis, serositis, complete cardiac block in newborns, or hematological abnormalities. If left untreated, lupus can be fatal as it progresses from attacks on the skin and joints to internal organs, such as the lungs, heart, and kidneys, with kidney disease being the most concerning. Kidney damage, measured by the amount of proteinuria in the urine, is one of the acute sites of injury associated with the pathogenicity of lupus and accounts for more than 50% of the disease's mortality and incidence. Currently, there is no definitive cure for lupus. From a practical standpoint, physicians generally use numerous immunosuppressants, such as high-dose corticosteroids, prednisone, azathioprine, or cyclophosphamide, but a significant number of these drugs present a problem in that they cause potentially harmful side effects to the patients being treated. The problem to be solved
[0007] The object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of nephritis or lupus accompanied by thrombosis, comprising a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[0008] [Chemical Formula 1]
[0009]
[0010] Another objective of the present invention is to provide a food composition for the prevention or improvement of nephritis or lupus accompanied by thrombosis, comprising a compound represented by the above formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[0011] Another objective of the present invention is to provide a therapeutic pharmaceutical composition for inhibiting nephritis or thrombosis of lupus disease, comprising a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[0012] Another object of the present invention is a pharmaceutical composition for the prevention or treatment of lupus accompanied by nephritis or thrombosis, comprising as an active ingredient a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, wherein
[0013] 1) Inhibit the activity of Germinal Center B cells or Plasma B cells, which are the B cells responsible for lupus, and
[0014] 2) To provide a pharmaceutical composition for inhibiting the expression of lupus autoantibodies IgG1, IgG2a, or IgG3. means of solving the problem
[0015] To achieve the above objective, the present invention provides a pharmaceutical composition for the prevention or treatment of nephritis or lupus accompanied by thrombosis, comprising a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[0016] [Chemical Formula 1]
[0017]
[0018] In addition, the present invention provides a food composition for the prevention or improvement of nephritis or lupus accompanied by thrombosis, comprising a compound represented by the above chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[0019] In addition, the present invention provides a therapeutic pharmaceutical composition for inhibiting nephritis or thrombosis of lupus disease, comprising a compound represented by the above chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[0020] In addition, the present invention relates to a pharmaceutical composition for the prevention or treatment of lupus accompanied by nephritis or thrombosis, comprising as an active ingredient a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, wherein
[0021] 1) Inhibit the activity of Germinal Center B cells or Plasma B cells, which are the B cells responsible for lupus, and
[0022] 2) Provides a pharmaceutical composition for inhibiting the expression of lupus autoantibodies IgG1, IgG2a, or IgG3. Effects of the invention
[0023] The present invention confirmed that the combined treatment of the novel compounds SD217 and FK506 under lupus disease conditions effectively inhibits the activity of lupus-associated B cells, namely Germinal Center B cells and Plasma B cells. Furthermore, by confirming that the levels of autoantibodies IgG1, IgG2a, and IgG3 are reduced, the invention demonstrated an effect of improving lupus, which can be usefully applied in related industries. Brief explanation of the drawing
[0024] Figure 1 is a figure confirming the inhibition of Germinal Center B cell (GC B cell) activity by combined treatment with SD217 and FK506 of the present invention using flow cytometry (A: flow cytometry results, B: quantification of flow cytometry results). Figure 2 is a figure confirming the inhibition of Plasma B cell activity by combined treatment with SD217 and FK506 of the present invention using flow cytometry (A: flow cytometry results, B: quantification of flow cytometry results). Figure 3 is a figure showing the expression of autoantibodies according to the combined treatment of SD217 and FK506 of the present invention, analyzed by ELISA (A: IgG1 quantification, B: IgG2a quantification, C: IgG3 quantification). Specific details for implementing the invention
[0025] To achieve the above objective, the present invention provides a pharmaceutical composition for the prevention or treatment of nephritis or lupus accompanied by thrombosis, comprising a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[0026]
[0027] The term "SD217 compound" of the present invention may be a compound represented by the above chemical formula 1 (1-(2,4-difluorophenyl)biguanide), and the above chemical formula is a compound disclosed in Korean Patent Application 10-2014-0110919.
[0028] The term “prevention” as used in this invention refers to any act of suppressing the symptoms of a specific disease or delaying its progression through the administration of the composition of this invention.
[0029] The term “treatment” as used in this invention refers to any act of improving or beneficially altering the symptoms of a specific disease through the administration of the composition of this invention.
[0030] The above pharmaceutically acceptable salt may include an acid addition salt formed by a pharmaceutically acceptable free acid, and the free acid may be an organic acid or an inorganic acid. The organic acid may include, but is not limited to, citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, metasulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, glutamic acid, aspartic acid, etc. Additionally, the above inorganic acid may include, but is not limited to, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, etc.
[0031] The pharmaceutical composition of the present invention may additionally include an adjuvant in addition to the active ingredient. Any adjuvant known in the art may be used without limitation, but, for example, Freund's complete or incomplete adjuvant may be further included to increase the effect.
[0032] The pharmaceutical composition according to the present invention may be prepared in a form in which an active ingredient is incorporated into a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients, and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers that can be used in the pharmaceutical composition of the present invention are not limited to these, but may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
[0033] The pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, external formulations, suppositories, or sterile injectable solutions, each according to conventional methods.
[0034] When formulating, the product may be prepared using diluents or excipients such as commonly used fillers, volume expanders, binders, wetting agents, disintegrants, and surfactants. Solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules, and such solid dosage forms may be prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc., with the active ingredient. In addition, lubricants such as magnesium stearate and talc may also be used in addition to simple excipients. Liquid dosage forms for oral administration include suspensions, liquid formulations, emulsions, and syrups, and may contain various excipients, such as wetting agents, sweeteners, flavoring agents, and preservatives, in addition to commonly used diluents such as water and liquid paraffin. Preparations for parenteral administration include sterile aqueous solutions, water-insoluble solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Water-insoluble solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Bases for suppositories may include Witepsol, Tween 61, cocoa paste, laurin paste, glycerogelatin, etc.
[0035] The pharmaceutical composition according to the present invention may be administered to an individual by various routes. Any mode of administration may be anticipated, for example, by oral, intravenous, intramuscular, subcutaneous, or intraperitoneal injection.
[0036] The dosage of the pharmaceutical composition according to the present invention is selected by taking into consideration the age, weight, gender, physical condition, etc. of the individual. It is obvious that the concentration of the active ingredient included in the pharmaceutical composition can be selected in various ways depending on the subject, and preferably, it is included in the pharmaceutical composition at a concentration of 0.01 to 5,000 μg / ml. If the concentration is less than 0.01 μg / ml, pharmaceutical activity may not appear, and if it exceeds 5,000 μg / ml, it may exhibit toxicity to the human body.
[0037] According to one embodiment of the present invention, the composition may further include a compound represented by the following chemical formula 2.
[0038]
[0039] The compound of Formula 2 of the present invention is also named FK506 or Tacrolimus, and Streptomyces taukuaensis It is an immunosuppressant produced by
[0040] According to one embodiment of the present invention, the composition may inhibit the activity of lupus-causing B cells, and the lupus-causing B cells may be germinal center B cells or plasma B cells.
[0041] According to one embodiment of the present invention, the composition may reduce the amount of autoantibodies, and the autoantibodies may be IgG1, IgG2a, or IgG3.
[0043] In addition, the present invention provides a food composition for the prevention or improvement of nephritis or lupus accompanied by thrombosis, comprising a compound represented by the above chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[0044] As used in the present invention, the term “improvement” refers to any action that at least reduces parameters related to the condition being treated, such as the degree of symptoms.
[0045] In addition to containing the active ingredient of the present invention, the food composition of the present invention may contain various flavoring agents or natural carbohydrates, etc., as additional ingredients, as in conventional food compositions.
[0046] Examples of the natural carbohydrates described above include monosaccharides, e.g., glucose, fructose, etc.; disaccharides, e.g., maltose, sucrose, etc.; polysaccharides, e.g., dextrin, cyclodextrin, etc., and conventional sugars, and sugar alcohols such as xylitol, sorbitol, erythritol, etc. The flavoring agents described above may advantageously use natural flavoring agents (taumatin), stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.). The food composition of the present invention may be formulated in the same manner as the pharmaceutical composition described above and used as a functional food or added to various foods. Foods to which the composition of the present invention may be added include, for example, beverages, meat, chocolate, food products, confectionery, pizza, ramen, other noodles, chewing gum, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplements.
[0047] In addition, the above food composition may contain, in addition to the extract which is an active ingredient, various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Furthermore, the food composition of the present invention may contain fruit pulp for the production of natural fruit juice, fruit juice beverages, and vegetable beverages.
[0048] The functional food composition of the present invention may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc., for the purpose of preventing or treating lupus. In the present invention, the term "health functional food composition" refers to a food manufactured and processed using raw materials or ingredients having functional properties useful to the human body pursuant to Article 6727 of the Act on Health Functional Foods, and means consuming it for the purpose of obtaining effects useful for health purposes, such as regulating nutrients or physiological actions regarding the structure and function of the human body. The health functional food of the present invention may include conventional food additives, and unless otherwise stipulated, suitability as a food additive is determined according to the specifications and standards for the relevant item in accordance with the general provisions and general test methods of the Food Additives Codex approved by the Ministry of Food and Drug Safety. Items listed in the aforementioned "Food Additives Codex" include, for example, chemical synthetic compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Examples include natural additives such as persimmon pigment, licorice extract, crystalline cellulose, sorghum pigment, and guar gum; and mixed preparations such as L-sodium glutamate preparations, alkaline additives for noodles, preservative preparations, and tar dye preparations. For example, a health functional food in tablet form may be produced by granulating a mixture of the active ingredient of the present invention with an excipient, a binder, a disintegrant, and other additives using a conventional method, and then adding a lubricant or the like and compression molding, or by directly compression molding the said mixture. In addition, the health functional food in tablet form may contain a binder or the like as needed. Among health functional foods in capsule form, hard capsules may be manufactured by filling a conventional hard capsule with a mixture of the active ingredient of the present invention mixed with additives such as excipients, and soft capsules may be manufactured by filling a capsule base such as gelatin with a mixture of the active ingredient of the present invention mixed with additives such as excipients. The above soft capsule may contain plasticizers such as glycerin or sorbitol, coloring agents, preservatives, etc., as needed.A health functional food in the form of a pill can be prepared by molding a mixture of the active ingredient of the present invention, excipients, binders, disintegrants, etc., using a previously known method, and if necessary, it can be coated with sucrose or other coating agents, or the surface can be coated with a substance such as starch or talc. A health functional food in the form of a granule can be prepared by making a mixture of the active ingredient of the present invention, excipients, binders, disintegrants, etc., into a granular form using a previously known method, and may contain flavoring agents, stimulating agents, etc., if necessary.
[0050] In addition, the present invention provides a therapeutic pharmaceutical composition for inhibiting nephritis or thrombosis of lupus disease, comprising a compound represented by the above chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[0052] In addition, the present invention relates to a pharmaceutical composition for the prevention or treatment of lupus accompanied by nephritis or thrombosis, comprising as an active ingredient a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, wherein
[0053] 1) Inhibit the activity of Germinal Center B cells or Plasma B cells, which are the B cells responsible for lupus, and
[0054] 2) Provides a pharmaceutical composition for inhibiting the expression of lupus autoantibodies IgG1, IgG2a, or IgG3.
[0056] The present invention will be explained in more detail below through examples. These examples are merely for the purpose of explaining the present invention more specifically, and it will be obvious to those skilled in the art that the scope of the present invention is not limited to these examples.
[0058] <Preparation Example 1> Synthesis and Preparation of SD217
[0059] To prepare SD217, a novel compound of the present invention, aniline was dissolved in acetonitrile, and then 1 equivalent of concentrated hydrochloric acid was added. Then, dicyanodiamide was added, the reaction mixture was heated to 175°C, and the crystalline substance was filtered out.
[0061] The chemical structure of the filtered substance in a crystalline state was identified and represented by Chemical Formula 1, and it was named SD217(1-(2,4-difluorophenyl)biguanide).
[0062] [Chemical Formula 1]
[0063]
[0065] <Example 1> Preparation of an in vitro lupus disease environment
[0066] To confirm the control effects of the novel compounds SD217 and FK506 of the present invention on lupus disease accompanied by nephritis or thrombosis, an environment of lupus disease accompanied by nephritis or thrombosis was induced. Specifically, B6 mouse splenocytes were treated with a CD3 antibody (anti-CD3) that causes the disease and a 10 μM R848 compound to induce an in vitro environment similar to lupus disease accompanied by nephritis or thrombosis. Subsequently, the cells were classified into a group treated with SD217 alone at a concentration of 500 μM (SD217); a group treated with FK506 alone at a concentration of 10 μM; and a group treated with SD217 and FK506 in combination (SD217+FK506), and stimulated at their respective concentrations (SD217 500 μM, FK506 10 μM). As controls, the nil group, the anti-CD3 group, and the anti-CD3 and R848 group (anti-CD3+R848) were used. As positive controls, the group administered 1 mM of metformin and the group administered metformin and FK506 in combination were used.
[0068] <Example 2> Confirmation of Inhibition of Lupus Pathogen B Cell Activity
[0069] <2-1> Confirmation of Germinal Center B Cell Activation Inhibition
[0070] In order to confirm the lupus disease control effects of the novel compounds SD217 and FK506 of the present invention, the activity of lupus pathogenic B cells, CD19+GL7+B cells (germinal center B cells, GC B cells), was analyzed by flow cytometry under the conditions of Example 1.
[0071] As a result, as shown in Figure 1, the activity of GC B cells increased under anti-CD3 and anti-CD3+R848 stimulation conditions compared to the nil group, but it was confirmed that the activity of GC B cells was significantly reduced by the combined administration of SD217 and FK506 of the present invention.
[0073] <2-2> Confirmation of Plasma B Cell Activation Inhibition
[0074] In order to determine whether the novel compounds SD217 and FK506 of the present invention inhibit the activity of Plasma B cells, the activity of CD19-CD138+ cells (plasma B cells) was analyzed by flow cytometry in the same manner as in Example 2-1.
[0076] As a result, as shown in Figure 2, plasma B cell activity increased in the anti-CD3 group and the anti-CD3+R848 group compared to the nil group, but it was confirmed that plasma B cell activity was significantly reduced by the combined administration of SD217 and FK506 of the present invention.
[0078] <Example 3> Evaluation of Antibody Regulation Efficacy
[0079] We intended to determine whether the combined administration of SD217 and FK506, novel compounds of the present invention, regulates autoantibodies associated with lupus disease. Specifically, the amounts of the lupus-causing autoantibodies IgG1, IgG2a, and IgG3 were measured by ELISA from the cell culture medium of Example 1.
[0081] As a result, as shown in Figure 3, the amounts of autoantibodies IgG1, IgG2a, and IgG3 in the anti-CD3 group and the anti-CD3+R848 group increased compared to the nil group, but it was confirmed that the amount of autoantibodies was significantly reduced by the combined administration of SD217 and FK506 of the present invention.
[0083] Accordingly, the present invention confirmed that the co-administration of the novel compounds SD217 and FK506 under lupus disease conditions effectively inhibits the activity of lupus-associated B cells, namely Germinal Center B cells and Plasma B cells. Furthermore, by confirming a reduction in the levels of the autoantibodies IgG1, IgG2a, and IgG3, the lupus improvement effect was verified.
Claims
Claim 1 A pharmaceutical composition for the prevention or treatment of lupus accompanied by nephritis or thrombosis comprising, as active ingredients a compound represented by the following Chemical Formula 1 and a compound represented by the following Chemical Formula 2, wherein the composition inhibits the activity of Germinal center B cells or Plasma B cells, which are B cells responsible for lupus: [Chemical Formula 1] ; and [Chemical Formula 2] . Claim 2 delete Claim 3 delete Claim 4 delete Claim 5 In claim 1, the composition is one that reduces the amount of autoantibodies. Claim 6 A composition according to claim 5, wherein the autoantibody is IgG1, IgG2a, or IgG3. Claim 7 A food composition for the prevention or improvement of lupus accompanied by nephritis or thrombosis comprising, as active ingredients a compound represented by the following Chemical Formula 1 and a compound represented by the following Chemical Formula 2, wherein the composition inhibits the activity of Germinal center B cells or Plasma B cells, which are B cells responsible for lupus: [Chemical Formula 1] ; and [Chemical Formula 2] . Claim 8 delete Claim 9 A pharmaceutical composition for therapeutic purposes that inhibits nephritis or thrombosis of lupus disease, comprising as active ingredients a compound represented by the following Chemical Formula 1 and a compound represented by the following Chemical Formula 2, wherein the composition inhibits the activity of Germinal Center B cells or Plasma B cells, which are B cells responsible for lupus: [Chemical Formula 1] ; and [Chemical Formula 2] . Claim 10 delete Claim 11 A pharmaceutical composition for the prevention or treatment of lupus accompanied by nephritis or thrombosis, comprising as active ingredients a compound represented by the following Chemical Formula 1 and a compound represented by the following Chemical Formula 2, wherein the composition comprises: 1) inhibiting the activity of Germinal Center B cells or Plasma B cells, which are lupus pathogenic B cells; and 2) inhibiting the expression of IgG1, IgG2a, or IgG3, which are lupus autoantibodies: [Chemical Formula 1] ; and [Chemical Formula 2] . Claim 12 delete Claim 13 A method for inhibiting the activity of Germinal center B cells and Plasma B cells, which are lupus-pathogenic B cells, or reducing the amounts of IgG1, IgG2a, and IgG3, which are lupus-pathogenic autoantibodies, comprising the step of co-treating cells in vitro in which a lupus-pathogenic environment accompanied by nephritis or thrombosis is induced with a compound represented by Chemical Formula 1 and a compound represented by Chemical Formula 2; [Chemical Formula 1] ; and [Chemical Formula 2] .
Citation Information
Patent Citations
Pharmaceutical composition for prevention or treatment of immune diseases or inflammatory disease comprising biguanide derivative compounds
KR1020150022731A
Composition for preventing or treating transplant rejection or post-transplant immune diseases comprising SD282 compound or calcineurin inhibitor
KR1020190045513A
